Table 3.

HRs and 95% CIs for cancer-specific death in CRC patients, for genes with versus without promoter hypermethylation

NSHDSCRUMS
n (%)*HR (95% CI)n (%)*HR (95% CI)
Methylated/unmethylatedUnivariateMultivariateMethylated/unmethylatedUnivariateMultivariate
CDKN2A49 (25.8)/1411.25 (0.76-2.04)1.21 (0.72-2.03)109 (28.4)/2751.67 (1.16-2.42)1.48 (1.00-2.19)
MLH118 (9.5)/1720.46 (0.16-1.24)0.65 (0.21-1.90)42 (10.9)/3420.45 (0.21-0.97)0.53 (0.23-1.19)
CACNA1G35 (18.4)/1551.46 (0.85-2.51)1.54 (0.85-2.77)63 (16.4)/3210.90 (0.54-1.46)0.77 (0.44-1.32)
NEUROG161 (32.1)/1291.37 (0.87-2.16)1.59 (0.95-2.65)109 (28.4)/2751.33 (0.91-1.94)1.30 (0.86-1.96)
RUNX343 (22.6)/1471.53 (0.93-2.53)1.65 (0.93-2.95)76 (19.8)/3081.09 (0.71-1.69)0.94 (0.57-1.52)
SOCS125 (13.2)/1651.23 (0.65-2.34)1.24 (0.62-2.48)49 (12.8)/3351.32 (0.81-2.13)1.35 (0.80-2.29)
IGF244 (23.2)/1461.72 (1.05-2.81)2.13 (1.19-3.82)69 (18.0)/3151.23 (0.79-1.92)0.93 (0.57-1.51)
CRABP159 (31.1)/1311.69 (1.08-2.67)1.61 (0.97-2.69)108 (28.1)/2761.19 (0.81-1.75)1.21 (0.79-1.84)
  • *Number of cases included in the survival analyses.

  • Percent of methylated reference >10.

  • Adjusted for sex, age at diagnosis, tumor location, tumor stage, and adjuvant chemotherapy.